Market Summary | Major Indices | Market Movers | Market Sectors | Mutual Funds | A-Z Stock Listings
ETF Screener | World Markets | Currencies | CEO Wealthmeter | Oil / Energy | Metals
Treasury Rates | Calculators | My Watchlist | My Portfolio
         Symbol Lookup
NEUROCRINE BIOSCNCE Add to My Watchlist (NSDQ: NBIX) 
Detailed Quote
News
Chart
SEC Filings
Profile
Historical
Options
     Neurocrine 2.37 +0.01 (+0.42%) 68,616
12780 El Camino Real
San Diego, CA 92130 US
(858) 617-7600
(858) 617-7601 fax
www.neurocrine.com
CEO Dr. Kevin C. Gorman, Ph.D.
Auditor Ernst & Young LLP
Exchange Traded NQ
ISIN Number US64125C1099
CIK Number 914475
NAICS Code 325414
Business Summary
The Company discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders.
Number of Employees 125
Share Fundamentals
Market Cap 104.43M
Shares Outstanding 44.06M
Float 38.31M
Short Interest 1.30M
Financial Strength
Revenue (TTM) $2,953,000
Earnings (TTM) -$51,038,000
Quick Ratio 2.4:1
Current Ratio 2.4:1
Total Debt/Equity 16.07:1
Profitability
Gross Margin N/A
EBITDA Margin N/A
Profit Margin N/A
Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Stock Updates provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs